Fig. 8
From: Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment
SAHA up-regulates genes associated with differentiation and/or growth inhibition in human breast cancer cells. (A) Identification of differentially expressed gene by differential display (DD). Total RNA was isolated from MCF7 cells treated with dimethylsulfoxide (DMSO) as control (Con), or suberoylanilide hydroxamic acid (SAHA) at 2 µM for 8 hr, and then subjected to DD as described in “Materials and Methods.” LH12, LH37, and LH38 are up-regulated bands observed in a DD gel. (B) Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) of mRNAs from genes matched by LH12 (isopentenyl-diphosphate delta isomerase; IDI1), and LH37/LH38 (1,25-dihydroxyvitamin D-3 up-regulated protein 1; VDUP1). Total RNA isolated from MCF7 cells treated with DMSO (Con), or SAHA at 2 µM for 8 hr, was reverse transcribed and subjected to PCR amplifications with specific primers. RT-PCR of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was included and served as a loading control. Shown are the amplified PCR products (413 bp for IDI1, 420 bp for VDUP1, and 450 bp for GAPDH). (C) SAHA induces gelsolin gene expression in MCF7 cells. Semi-quantitative RT-PCR of gelsolin mRNA was carried out essentially the same as described above. The amplified PCR product for gelsolin is 270 bp.